

Western Pacific Region, 2016


Global Vaccine Action Plan (GVAP) and Regional framework indicators

| | | | |
|---|---------------------|---|---------------------------|
| Polio-free status sustained | Yes | Countries and areas that introduced at least one dose of IPV by end of 2015 | 34/36 |
| Countries and areas achieved MNT elimination | 34/36 | Countries and areas that reported increasing trend in domestic expenditure since 2010 | 6/36 |
| Countries and areas verified for measles elimination | 7/36 | Countries and areas that established a NITAG (with administrative/legal basis only) | 12/36 |
| Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to < 1% in 5 year olds by 2017 | Yes | Countries and areas that established a functional NITAG (legal basis, TORs, ≥ 5 areas of expertise, ≥ 1 meeting per year, agenda and background docs, disclosure of conflict of interest) | 7/36 |
| Countries and areas introduced at least one new or underutilized vaccine since 2010* | 27/36 (14/19 L/MIC) | Countries and areas at risk for JE that introduced JE vaccine | 8/12 |
| DTP3 regional immunization coverage ≥ 95% by 2020 | 97.5% | Countries and areas with primary series JE vaccine ≥ 90% coverage among children under 15 years old | 4/8 |
| Countries and areas with DTP3 coverage ≥ 90% in all districts (proportion of districts with ≥ 90% coverage) | 10/36 (90.7%) | Countries and areas with established case-based surveillance for invasive bacterial vaccine-preventable disease | 6/36 |
| Sustained DTP3 regional coverage ≥ 95% for three or more years | No | Countries and areas with established case-based surveillance for rotavirus disease | 8/36 |
| Countries and areas with DTP dropout rate < 5% | 16/36 | Countries and areas with rubella and CRS case-based data submitted to WPRO | 32/36 rubella 0/36 CRS |

* New or underutilized vaccines include Hib, HPV, PCV and RV only for the Regional-level indicator. Information on other vaccines' introduction is reported in country profiles.

| Population | |
|---|---------------|
| Total | 1 866 319 076 |
| Births | 23 720 909 |
| NIP target < 1 year (surviving infants) | 23 686 303 |

* United Nations World Population Prospects: The 2015 Revision



Source: World Bank Open Data as of June 2017

| Gavi Eligibility | |
|----------------------|---|
| Gavi eligible | 1 (Cambodia) |
| Transitioning | 4 (Lao People's Democratic Republic, Papua New Guinea, Solomon Islands, Viet Nam) |
| Fully self-financing | 2 (Kiribati, Mongolia) |
| Not eligible | 29 countries/areas |

Reported cases of selected vaccine preventable diseases


| Year | Acute flaccid paralysis (AFP) | | Measles | | Rubella | | Congenital rubella syndrome (CRS) | | Neonatal tetanus | | Total tetanus | | Diphtheria | | Pertussis | |
|------|-------------------------------|----------------------|---------|------|---------|------|-----------------------------------|-----|------------------|-----|---------------|-----|------------|-----|-----------|-----|
| | Non-polio AFP rate | % adequate specimens | Cases | IR | Cases | IR | Cases | IR | Cases | IR | Cases | IR | Cases | IR | Cases | IR |
| 2012 | 2.3 | 91% | 10 758 | 5.9 | 44 325 | 24.4 | 137 | 0.0 | 911 | 0.0 | 1321 | 0.1 | 142 | 0.0 | 43 264 | 2.4 |
| 2013 | 2.0 | 91% | 31 885 | 17.2 | 33 703 | 18.1 | 46 | 0.0 | 679 | 0.0 | 2127 | 0.1 | 43 | 0.0 | 22 719 | 1.2 |
| 2014 | 2.1 | 90% | 131 094 | 70.1 | 12 822 | 6.9 | 12 | 0.0 | 578 | 0.0 | 1704 | 0.1 | 22 | 0.0 | 19 162 | 1.0 |
| 2015 | 2.0 | 90% | 65 195 | 35.1 | 9407 | 5.1 | 5 | 0.0 | 470 | 0.0 | 1746 | 0.1 | 226 | 0.0 | 34 708 | 1.9 |
| 2016 | 2.1 | 90% | 57 888 | 31.0 | 5450 | 2.9 | 19 | 0.0 | 326 | 0.0 | 1710 | 0.1 | 98 | 0.0 | 30 520 | 1.6 |

Non-polio AFP rate = incidence per 100 000 under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset
IR = incidence rate: for measles and rubella, per 1 000 000 population; for CRS and neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.
Population source: United Nations World Population Prospects

Invasive bacterial disease, rotavirus and Japanese encephalitis


| Year | Rotavirus diarrhea | | Japanese encephalitis | | Invasive bacterial disease | | | |
|------|----------------------------|-----------------|----------------------------|-----------------|----------------------------|-----|--------------|---------------|
| | No. of countries reporting | Confirmed cases | No. of countries reporting | Confirmed cases | No. of countries reporting | Hib | Pneumococcus | Meningococcus |
| 2014 | 16 | 10 659 | 13 | 1420 | 14 | 37 | 1782 | 116 |
| 2015 | 17 | 12 208 | 19 | 1120 | 21 | 21 | 2375 | 119 |
| 2016 | 14 | 11 804 | 17 | 1796 | 17 | 19 | 2205 | 120 |

Confirmed and compatible measles cases by month of onset, 2012–2016



* Data from measles and rubella surveillance data, submitted monthly to WHO

Measles incidence rate of laboratory-confirmed, epi-linked and compatible cases, 2016



* Data from measles and rubella surveillance data, submitted monthly to WHO